GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oculis Holding AG (NAS:OCS) » Definitions » Debt-to-EBITDA

Oculis Holding AG (Oculis Holding AG) Debt-to-EBITDA : -0.01 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Oculis Holding AG Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Oculis Holding AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.21 Mil. Oculis Holding AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.46 Mil. Oculis Holding AG's annualized EBITDA for the quarter that ended in Mar. 2024 was $-71.79 Mil. Oculis Holding AG's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -0.01.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Oculis Holding AG's Debt-to-EBITDA or its related term are showing as below:

OCS' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.07   Med: -0.04   Max: -0.01
Current: -0.01

During the past 4 years, the highest Debt-to-EBITDA Ratio of Oculis Holding AG was -0.01. The lowest was -0.07. And the median was -0.04.

OCS's Debt-to-EBITDA is ranked worse than
100% of 277 companies
in the Biotechnology industry
Industry Median: 1.36 vs OCS: -0.01

Oculis Holding AG Debt-to-EBITDA Historical Data

The historical data trend for Oculis Holding AG's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oculis Holding AG Debt-to-EBITDA Chart

Oculis Holding AG Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
-0.07 -0.06 -0.02 -0.01

Oculis Holding AG Quarterly Data
Dec20 Jun21 Sep21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -0.01 -0.01 -0.01 -0.01

Competitive Comparison of Oculis Holding AG's Debt-to-EBITDA

For the Biotechnology subindustry, Oculis Holding AG's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oculis Holding AG's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oculis Holding AG's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Oculis Holding AG's Debt-to-EBITDA falls into.



Oculis Holding AG Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Oculis Holding AG's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.201 + 0.498) / -100.709
=-0.01

Oculis Holding AG's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.205 + 0.463) / -71.792
=-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Oculis Holding AG  (NAS:OCS) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Oculis Holding AG Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Oculis Holding AG's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Oculis Holding AG (Oculis Holding AG) Business Description

Traded in Other Exchanges
Address
Bahnhofstrasse 7, Zug, CHE, 6300
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.